Liminatus Pharma, Inc. acquires InnocsAI LLC (2026)

Deal facts

Buyer: Liminatus Pharma, Inc.
Target: InnocsAI LLC
Deal value: Not disclosed
Announced: 29 June 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: shares

Sources

What we know

Liminatus Pharma, Inc. has agreed to acquire InnocsAI LLC in a strategic acquisition within the healthcare sector. The transaction involves a share-based consideration structure, with both the buyer and the target operating from the United States. The deal was officially announced on 29 June 2026 and was completed just three days later on 2 July 2026. The specific financial value of the transaction has not been disclosed to the public, and no currency was reported for the deal.

This acquisition represents a significant consolidation within the US healthcare landscape, bringing together two domestic entities to expand their combined capabilities. The rapid timeline between the announcement and completion suggests a streamlined approval process for the parties involved. As the transaction has already been finalised, the companies are now operating under a unified structure. The transaction is subject to regulatory approval.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

2 Jul 2026CompletedClosed
Liminatus Pharma, Inc. completes acquisition of InnocsAI LLC
Item 1.01 Entry into a Material Definitive Agreement. Amended and Restated Merger Agreement On June 29, 2026, Liminatus Pharma, Inc. (the “Company”), InnocsAI LLC, a Delaware limited liability company (“InnocsAI”), and NamChul Jung, an individual, as the representative of the members of InnocsAI, entered into an Amended and Restated Merger Agreement (the “Amended and Restated Merger Agreement”), w
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of InnocsAI LLC by Liminatus Pharma, Inc. Announced on 29 June 2026, this strategic move in the US healthcare sector underscores a shift toward integrating artificial intelligence directly into pharmaceutical workflows. The deal structure is notable for its reliance solely on shares as consideration. This mechanism aligns the financial interests of the InnocsAI founders with the long-term trajectory of Liminatus, yet it also introduces specific liquidity constraints that differ significantly from cash exits. For the SME founder reading this, the choice of share-based consideration often reflects a buyer seeking to preserve cash while betting on future synergy value, but it places the exit value entirely in the hands of market performance post-closing.

The absence of a disclosed value figure is typical for private share-swap transactions where valuation is embedded in the exchange ratio rather than a headline number. This structure demands that the selling founder understands the mechanics of the new shareholding. Unlike a cash deal where the exit is immediate and final, a share deal creates an ongoing relationship with the acquirer. Regulatory scrutiny in the US healthcare space remains robust, particularly regarding data privacy and clinical validation of AI tools. While the deal is marked as completed, the integration phase will likely face scrutiny from bodies overseeing medical device software and data security. Founders must ensure their due diligence covered not just commercial fit but also the regulatory path for the combined entity, as change-of-control covenants in healthcare can trigger unexpected compliance reviews.

We believe this transaction highlights a broader trend where technology providers are no longer just vendors but are becoming core assets for traditional pharma players. The strategic nature of the acquisition suggests Liminatus views InnocsAI's capabilities as essential to its future product roadmap rather than a peripheral add-on. This distinction matters for how the founders will be treated post-close. In a true strategic integration, the original team often retains significant operational influence, whereas in a financial buyout, they might face rapid restructuring. The share consideration reinforces this by keeping the founders invested in the success of the integration, effectively turning them into long-term stakeholders in the merged entity.

Your immediate action this week should be to audit your own cap table for any change-of-control clauses that might trigger in a share-swap scenario. Many founders overlook how a pure share deal can alter their voting rights or unlock different exit restrictions compared to a cash transaction. Review your shareholder agreements now to understand if a share-for-share exchange requires board approval or triggers a mandatory buyback option that could force an unwanted liquidity event.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from Liminatus Pharma, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

11 August 2026ClearedHealthcare

Dolby Medical Home Respiratory Care Limited (Vivisol) to acquire Air Liquide Healthcare Limited’s home oxygen services business

Dolby Medical Home Respiratory Care Limited, trading as Vivisol, has agreed to acquire the home oxygen services business of Air Liquide Healthcare Limited in a strategic…

Buyer: Dolby Medical Home Respiratory Care Limited (Vivisol)
Target: Air Liquide Healthcare Limited’s home oxygen services business
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

10 August 2026Firm intentionHealthcare

RSLGH, LLC to acquire RYTHM, Inc.

RSLGH, LLC has agreed to acquire RYTHM, Inc., a healthcare company based in the United States, in a strategic acquisition valued at $109.5 million. The transaction invol…

Buyer: RSLGH, LLC
Target: RYTHM, Inc.
Deal value: USD 109,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

5 August 2026CompletedHealthcare

Ensysce Biosciences, Inc. to acquire Cy Biopharma, Inc.

Ensysce Biosciences, Inc. has agreed to acquire Cy Biopharma, Inc. in a strategic acquisition within the healthcare sector. The transaction was announced on 5 August 202…

Buyer: Ensysce Biosciences, Inc.
Target: Cy Biopharma, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

31 July 2026Firm intentionHealthcare

Profusa, Inc. to acquire G3 Vision Labs Inc.

Profusa, Inc. has agreed to acquire G3 Vision Labs Inc. in a strategic acquisition within the healthcare sector. The transaction involves the exchange of shares as the p…

Buyer: Profusa, Inc.
Target: G3 Vision Labs Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history